

DAFTAR PUSTAKA

- Agarwala, P., & Salzman, S. H. (2020). Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement. *Chest*, *157*(3), 603–611. <https://doi.org/10.1016/j.chest.2019.10.014>
- Amarsheda, S., & Bhise, A. (2021). Association of Fatigue, Quality of Life and Functional Capacity in Breast Cancer Patients Receiving Adjuvant Chemotherapy. *Asian Pacific Journal of Cancer Care*, *6*, 59–64. <https://doi.org/10.31557/apjcc.2021.6.1.59-64>
- American Thoracic Society. (2002). ATS statement: guidelines for the six-minute walk test. *American Journal of Respiratory and Critical Care Medicine*, *166*(1), 111–117. <https://doi.org/10.1164/ajrccm.166.1.at1102>
- Andersen, K. G., Jensen, M.-B., Kehlet, H., Gärtner, R., Eckhoff, L., & Kroman, N. (2012). Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. *Acta Oncologica (Stockholm, Sweden)*, *51*(8), 1036–1044. <https://doi.org/10.3109/0284186X.2012.692884>
- Anthis, N. J., & Kavanaugh-Lynch, M. H. E. (2020). The Global Challenge to Prevent Breast Cancer: Surfacing New Ideas to Accelerate Prevention Research. In *International journal of environmental research and public health* (Vol. 17, Issue 4). <https://doi.org/10.3390/ijerph17041394>
- Bjelic-Radicic, V., Cardoso, F., Cameron, D., Brain, E., Kuljanic, K., da Costa, R. A., Conroy, T., Inwald, E. C., Serpentine, S., Pinto, M., Weis, J., Morag, O., Lindviksmoen Astrup, G., Tomaszewski, K. A., Pogoda, K., Sinai, P., Sprangers, M., Aaronson, N., Velikova, G., ... Bottomley, A. (2020). An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. *Annals of Oncology : Official Journal of the European Society for Medical Oncology*, *31*(2), 283–288. <https://doi.org/10.1016/j.annonc.2019.10.027>
- Boehm, D. U., Lebrecht, A., Schmidt, M., Siggelkow, W., Lindner, C., Litz, A., Ulbrich, E., & Koelbl, H. (2007). Prognostic impact of haemoglobin levels in breast cancer. *Anticancer Research*, *27*(2), 1223–1226.
- But-Hadzic, J., Dervisevic, M., Karpljuk, D., Videmsek, M., Dervisevic, E., Paravlic, A., Hadzic, V., & Tomazin, K. (2021). Six-Minute Walk Distance in Breast Cancer Survivors-A Systematic Review with Meta-Analysis. *International Journal of Environmental Research and Public Health*, *18*(5). <https://doi.org/10.3390/ijerph18052591>
- Costa, A. R., Fontes, F., Pereira, S., Gonçalves, M., Azevedo, A., & Lunet, N. (2014). Impact of breast cancer treatments on sleep disturbances - A systematic review. *Breast (Edinburgh, Scotland)*, *23*(6), 697–709. <https://doi.org/10.1016/j.breast.2014.09.003>
- Dolan, L. B., Gelmon, K., Courneya, K. S., Mackey, J. R., Segal, R. J., Lane, K., Reid, R. D., & McKenzie, D. C. (2010). Hemoglobin and Aerobic Fitness

Changes with Supervised Exercise Training in Breast Cancer Patients Receiving Chemotherapy. *Cancer Epidemiology, Biomarkers & Prevention*, 19(11), 2826–2832. <https://doi.org/10.1158/1055-9965.EPI-10-0521>

du Toit, G. C., & Kidd, M. (2015). Prospective quality of life study of South African women undergoing treatment for advanced-stage cervical cancer. *Clinical Therapeutics*, 37(10), 2324–2331. <https://doi.org/10.1016/j.clinthera.2015.08.018>

Galiano-Castillo, N., Arroyo-Morales, M., Ariza-Garcia, A., Sánchez-Salado, C., Fernández-Lao, C., Cantarero-Villanueva, I., & Martín-Martín, L. (2016). The Six-Minute Walk Test as a Measure of Health in Breast Cancer Patients. *Journal of Aging and Physical Activity*, 24(4), 508–515. <https://doi.org/10.1123/japa.2015-0056>

Howden, E. J., Bigaran, A., Beaudry, R., Fraser, S., Selig, S., Foulkes, S., Antill, Y., Nightingale, S., Loi, S., Haykowsky, M. J., & La Gerche, A. (2019). Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. *European Journal of Preventive Cardiology*, 26(3), 305–315. <https://doi.org/10.1177/2047487318811181>

Jones, L. W., Eves, N. D., Mackey, J. R., Peddle, C. J., Haykowsky, M., Joy, A. A., Courneya, K. S., Tankel, K., Spratlin, J., & Reiman, T. (2007). Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. *Lung Cancer (Amsterdam, Netherlands)*, 55(2), 225–232. <https://doi.org/10.1016/j.lungcan.2006.10.006>

Kenemans, P. (2007). Quality of life in breast cancer patients. *Gynecological Endocrinology*, 23(7), 366–367. <https://doi.org/10.1080/09513590701563190>

Kirshner, J., Hatch, M., Hennessy, D. D., Fridman, M., & Tannous, R. E. (2004). Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. *The Oncologist*, 9(1), 25–32. <https://doi.org/10.1634/theoncologist.9-1-25>

Klassen, O., Schmidt, M. E., Scharhag-Rosenberger, F., Sorkin, M., Ulrich, C. M., Schneeweiss, A., Potthoff, K., Steindorf, K., & Wiskemann, J. (2014). Cardiorespiratory fitness in breast cancer patients undergoing adjuvant therapy. *Acta Oncologica (Stockholm, Sweden)*, 53(10), 1356–1365. <https://doi.org/10.3109/0284186X.2014.899435>

Laufer-Perl, M. (2020). Cancer Therapeutic Related Cardiac Dysfunction Among Patients with Active Breast Cancer. *IMAJ*.

Lôbo, S. A., Fernandes, A. F. C., Almeida, P. C. de, Carvalho, C. M. de L., & Sawada, N. O. (2014). Quality of life in women with breast cancer undergoing chemotherapy. *Acta Paulista de Enfermagem*, 27(6), 554–559. <https://doi.org/10.1590/1982-0194201400090>

Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., Schneider, M., & Schrijvers, D. (2004). The European Cancer Anaemia Survey (ECAS): a

large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. *European Journal of Cancer (Oxford, England : 1990)*, *40*(15), 2293–2306.
<https://doi.org/10.1016/j.ejca.2004.06.019>

- Morales, J. S., Valenzuela, P. L., Rincón-Castanedo, C., Takken, T., Fiuza-Luces, C., Santos-Lozano, A., & Lucia, A. (2018). Exercise training in childhood cancer: A systematic review and meta-analysis of randomized controlled trials. *Cancer Treatment Reviews*, *70*, 154–167.
<https://doi.org/10.1016/j.ctrv.2018.08.012>
- Ortiz, A., Tirado, M., Hughes, D. C., Gonzalez, V., Song, J., Mama, S. K., & Basen-Engquist, K. (2018). Relationship between physical activity, disability, and physical fitness profile in sedentary Latina breast cancer survivors. *Physiotherapy Theory and Practice*, *34*(10), 783–794.
<https://doi.org/10.1080/09593985.2018.1424978>
- Peel, A. B., Thomas, S. M., Dittus, K., Jones, L. W., & Lakoski, S. G. (2014). Cardiorespiratory fitness in breast cancer patients: a call for normative values. *Journal of the American Heart Association*, *3*(1), e000432.
- Ramachandran, S., Sudhakar, S., Thaslim, F., Kirthika, S. V., Padmanabhan, K., & Samuel, A. J. (2018). Beware! Reduced Functional Capacity and Quality of Life with Increased Fatigue Level among the Breast Cancer Survivors Undergoing Chemotherapy in India. *Indian Journal of Palliative Care*, *24*(1), 117–118. https://doi.org/10.4103/IJPC.IJPC_170_17
- Rostagno, C., Olivo, G., Comeglio, M., Boddi, V., Banchelli, M., Galanti, G., & Gensini, G. F. (2003). Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation. *European Journal of Heart Failure*, *5*(3), 247–252.
[https://doi.org/10.1016/s1388-9842\(02\)00244-1](https://doi.org/10.1016/s1388-9842(02)00244-1)
- Schwartz, R. N. (2007). Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. *American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists*, *64*(3 Suppl 2), S5-13; quiz S28-30. <https://doi.org/10.2146/ajhp060601>
- Shinano, H., Miyazaki, S., Miura, K., Ohtsu, H., Yonemoto, N., Matsuoka, K., Konishi, H., Daida, H., Saito, M., & Sase, K. (2020). Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab. *Circulation Reports*, *2*(4), 235–242. <https://doi.org/10.1253/circrep.CR-19-0119>
- Siagian, T. W. (2018). Association between Left Ventricular Global Longitudinal Strain and Six Minute Walk Test Before and After Chemotherapy with Anthracycline in Breast Cancer Patients. *International Journal of ChemTech Research*.
- Torres, C. (2020). *Cardiac dysfunction in breast cancer patients treated with anthracyclines: a singlecenter experience*.

- van Waart, H., Stuiver, M. M., van Harten, W. H., Geleijn, E., Kieffer, J. M., Buffart, L. M., de Maaker-Berkhof, M., Boven, E., Schrama, J., Geenen, M. M., Meerum Terwogt, J. M., van Bochove, A., Lustig, V., van den Heiligenberg, S. M., Smorenburg, C. H., Hellendoorn-van Vreeswijk, J. A. J. H., Sonke, G. S., & Aaronson, N. K. (2015). Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 33(17), 1918–1927. <https://doi.org/10.1200/JCO.2014.59.1081>
- Vardar Yağlı, N., Şener, G., Arıkan, H., Sağlam, M., İnal İnce, D., Savcı, S., Çalık Kutukcu, E., Altundağ, K., Kaya, E. B., Kutluk, T., & Özışık, Y. (2015). Do yoga and aerobic exercise training have impact on functional capacity, fatigue, peripheral muscle strength, and quality of life in breast cancer survivors? *Integrative Cancer Therapies*, 14(2), 125–132. <https://doi.org/10.1177/1534735414565699>
- Wasserman, K. (1997). Diagnosing cardiovascular and lung pathophysiology from exercise gas exchange. *Chest*, 112(4), 1091–1101. <https://doi.org/10.1378/chest.112.4.1091>
- Ying, L., Yahng, J.-M. J., Fisher, M., Simons, K., & Nightingale, S. (2020). Walking the boundaries: using the 6-min walk test for accurate assessment of the level of fitness in breast clinic outpatients. *ANZ Journal of Surgery*, 90(6), 1141–1145. <https://doi.org/10.1111/ans.15637>

Lampiran Persetujuan Etik



REKOMENDASI PERSETUJUAN ETIK
 Nomor : 363/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 25 Juli 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22050219	No Sponsor Protokol	
Peneliti Utama	dr. Diza Khairina Mukhlisa	Sponsor	
Judul Peneliti	PENGARUH LATIHAN FISIK TERHADAP PERUBAHAN KAPASITAS FUNGSIONAL DAN KUALITAS HIDUP PADA PASIEN KANKER PAYUDARA YANG MENJALANI KEMOTERAPI		
No Versi Protokol	2	Tanggal Versi	15 Juli 2022
No Versi PSP	2	Tanggal Versi	15 Juli 2022
Tempat Penelitian	RS Universitas Hasanuddin dan RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 2 Juni 2022	Masa Berlaku 25 Juli 2022 sampai 25 Juli 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

DATA

No. Sampel	Umur (Tahun)	Obat Kemoterapi	Jarak Pre-Kemoterapi	Jarak Post-Kemoterapi	VO2 Max Pre-Kemoterapi	VO2 Max Post-Kemoterapi	METs Pre-Kemoterapi	METs Post Kemoterapi
1	54	Doxorubicin 80mg + Docetaxel 110 mg	389	340	21,104	18,164	6,02971429	5,18971429
2	46	Paxus 300 miligram per intravena, epirubicin 80 miligram per intravena	345	280	19,556	15,656	5,58742857	4,47314286
3	44	Paclitaxel 250 mg + Epirubicin 75 mg + Cyclophosphamide 750 mg	335	288	18,176	15,356	5,19314286	4,38742857
4	28	Doxorubicin 90mg + Cyclophosphamide 900mg	288	245	16,864	14,284	4,81828571	4,08114286
5	46	Brexel 120mg + Doxorubicin 80mg + Cyclophosphamide 800mg	325	270	17,68	14,38	5,05142857	4,10857143
6	41	Paclitaxel 260mg, Epirubicin 70mg, Cyclophosphamide 700mg	326	290	18,416	16,256	5,26171429	4,64457143
7	45	Paclitaxel 270mg + Epirubicin 90mg	328	270	17,756	14,276	5,07314286	4,07885714
8	36	Brexel 120mg + Doxorubicin 85mg + Cyclophosphamide 850 mg	380	350	22,956	21,156	6,55885714	6,04457143
9	46	Brexel 120mg + Doxorubicin 82mg + Cyclophosphamide 800mg	285	245	15,644	13,244	4,46971429	3,784
10	55	Brexel 120mg + Doxorubicin 80mg + Cyclophosphamide 800mg	369	335	18,76	16,72	5,36	4,77714286
11	47	Brexel 120mg + Doxorubicin 80mg + Cyclophosphamide 800mg	289	245	16,352	13,712	4,672	3,91771429
12	42	Doxorubicin 70mg + Paclitaxel 260mg	288	250	16,032	13,752	4,58057143	3,92914286

13	34	doxorubicin 100mg + Cyclophosphamide 1000mg + Docetaxel 180mg	310	275	19,172	17,072	5,47771429	4,87771429
14	63	Fankopac 330mg + Epirubicin 80mg	285	245	13,096	10,696	3,74171429	3,056
15	39	Doxorubicin 90mg + Cyclophosphamide 900mg	388	355	22,032	20,052	6,29485714	5,72914286
16	60	brexel 80 mg perintravena, doxorubicin 50 mg per intravena, cisplatin 50 mg per intraperintravena	325	288	15,964	13,744	4,56114286	3,92685714
17	53	Brexel 130mg, Epirubicin 80mg	438	415	24,252	22,872	6,92914286	6,53485714
18	61	Brexel 110mg + Epirubicin 70mg + Cyclophosphamide 700mg	310	285	15,012	13,512	4,28914286	3,86057143
19	51	Brexel 120 miligram per intravena, Doxorubicin 80 mg miligram per intravena, cyclophosphamide 800 miligram per intravena	326	295	16,752	14,892	4,78628571	4,25485714
20	50	Paclitaxel 270mg + Epirubicin 90mg	347	310	17,96	15,74	5,13142857	4,49714286
21	53	Brexel 120 miligram per intravena, Doxorubicin 80 mg miligram per intravena, cyclophosphamide 800 miligram per intravena	359	315	19,356	16,716	5,53028571	4,776
22	60	Brexel 120 miligram per intravena, Doxorubicin 80 mg miligram per intravena, cyclophosphamide 800 miligram per intravena	348	310	17,916	15,636	5,11885714	4,46742857
23	44	Fankopac 330mg + Epirubicin 80mg	312	270	17,316	14,796	4,94742857	4,22742857
24	47	Brexel 130mg, Epirubicin 80mg	421	400	23,856	22,596	6,816	6,456

25	63	Paclitaxel 270mg + Epirubicin 90mg	326	285	15,608	13,148	4,45942857	3,75657143
26	44	Brexel 120 miligram per intravena, Doxorubicin 80 mg miligram per intravena, cyclophosphamide 800 miligram per intravena	317	265	17,148	14,028	4,89942857	4,008
27	44	Cyclophosphamide 800 mg, doxorubicin 80 mg, 5-FU 800 mg	354	324	19,524	17,724	5,57828571	5,064
28	60	Fonkopac (Cisplatin) 330mg + Epirubicin 80mg	367	344	18,796	17,416	5,37028571	4,976
29	44	Brexel 120mg + Doxorubicin 80mg + Cyclophosphamide 800mg	294	250	16,756	14,116	4,78742857	4,03314286
30	51	Brexel + Doxorubicin + Cyclophosphamide	379	345	21,076	19,036	6,02171429	5,43885714
31	38	Brexel + Doxorubicin + Cyclophosphamide	378	345	20,756	18,776	5,93028571	5,36457143
32	47	Doxorubicin 70mg + Paclitaxel 260mg	318	265	16,896	13,716	4,82742857	3,91885714
33	51	Brexel + Doxorubicin + Cyclophosphamide	315	265	16,3	13,3	4,65714286	3,8
34	58	Paclitaxel + Epirubicin + Cyclophosphamide	446	420	23,068	21,508	6,59085714	6,14514286
35	55	Paclitaxel + Epirubicin + Cyclophosphamide	327	270	18,06	14,64	5,16	4,18285714
36	55	doxorubicin 100mg + Cyclophosphamide 1000mg + Docetaxel 180mg	364	328	19,656	17,496	5,616	4,99885714
37	51	docetaxel 100 miligram per intravena, epirubicin 75 miligram per intravena	364	325	19,708	17,368	5,63085714	4,96228571
38	60	Paclitaxel + Epirubicin + Cyclophosphamide	445	430	23,684	22,784	6,76685714	6,50971429
39	38	Doxorubicin + Paclitaxel	350	325	19,544	18,044	5,584	5,15542857

40	65	Paclitaxel 280mg + Epirubicin 80mg + Cyclophosphamide 800mg	388	350	19,484	17,204	5,56685714	4,91542857
41	70	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	326	285	14,724	12,264	4,20685714	3,504
42	58	Brexel + Doxorubicin + Cyclophosphamide	410	375	21,636	19,536	6,18171429	5,58171429
43	56	Brexel + Doxorubicin + Cyclophosphamide	326	270	16,336	12,976	4,66742857	3,70742857
44	32	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	410	375	24,08	21,98	6,88	6,28
45	44	Paclitaxel + Epirubicin + Cyclophosphamide	296	245	15,732	12,672	4,49485714	3,62057143
46	48	Paclitaxel + Epirubicin + Cyclophosphamide	293	252	15,032	12,572	4,29485714	3,592
47	46	Brexel 110mg + Epirubicin 70mg + Cyclophosphamide 700mg	432	410	24,464	23,144	6,98971429	6,61257143
48	49	Doxorubicin 90mg + Cyclophosphamide 900mg	364	328	19,552	17,392	5,58628571	4,96914286
49	42	Paclitaxel 260mg, Epirubicin 70mg, Cyclophosphamide 700mg	355	310	20,572	17,872	5,87771429	5,10628571